Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab

New agreement covers 1.25 million additional doses of the antibody cocktail, bringing the total potential US supply to over 1.5 million dosesCasirivimab and imdevimab were granted U.S. FDA Emergency Use Authorization for recently-diagnosed, high-risk, mild to moderate COVID-19 patientsRoche and Regeneron are collaborating on developing and manufacturing casirivimab and imdevimab; Regeneron is distributing the antibody cocktail in the US and Roche will be responsible for distribution outside the USBasel, 12 January 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron’s casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed. The US government said it will provide these additional doses at no cost to patients, though healthcare facilities may charge fees related to administration, and will continue to coordinate allocation of the antibody cocktail to state and territorial health departments.·  a high-volume molecular test to detect SARS-CoV-2, the virus that causes COVID-19, (FDA Emergency Use Authorisation (EUA) and available in countries accepting the CE Mark)
·  a SARS-CoV-2 laboratory-based antibody test, aimed at detecting the presence of antibodies in the blood targeting the nucleocapsid (FDA EUA and CE Mark)
·  an IL-6 test to assist in identifying severe inflammatory response in patients with confirmed COVID-19 (FDA EUA and CE Mark) 
·  Roche v-TAC, which could help simplify the screening, diagnosis and monitoring of patients with respiratory compromise in the current COVID-19 pandemic
·  a SARS-CoV-2 rapid antibody test to help determine at the point of care whether a person has been exposed to the virus (CE Mark)
·  a rapid antigen test to support in the detection of SARS-CoV-2 at the point of care within 15 minutes (CE Mark) 
·  a high-volume molecular test to simultaneously detect and differentiate between SARS-CoV-2 and influenza A/B, as the symptoms are similar for both (FDA EUA and CE Mark)
·  a second SARS-CoV-2 antibody test, aimed at measuring the spike protein to support vaccination development and complement our existing portfolio
·  a point-of-care molecular PCR test that simultaneously detects and differentiates between SARS-CoV-2 and influenza A/B infections to support urgent triage and diagnosis (FDA EUA and CE Mark)Our research into therapies:
Roche is committed to improving the treatment of COVID-19. We are actively involved in understanding the potential of our existing portfolio and are exploring the potential of our investigational molecules.
Attachment12012021_MR_BARDA supply agreement